Skip to main content
TipRanks
Go Ultimate75% OFF

China NT Pharma Group Co., Ltd. (1011) Stock Price & Analysis

2 Followers

1011 Stock Chart & Stats

HK$0.19-HK$0.02(-8.10%)
At close: 4:00 PM GMT+8
HK$0.2HK$0.3HK$0.4Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
HKD 0.19 - HKD 0.20
52-Week Range
HKD 0.16 - HKD 1.00
Previous Close
HKD 0.21
Volume
N/A
Average Volume (3M)
394.99K
Market Cap
HKD 346.74M
Enterprise Value
HKD 787.72M
Total Cash (Recent Filing)
HKD 11.91M
Total Debt (Recent Filing)
HKD 334.93M
Price to Earnings (P/E)
―
Beta
1.10
Next Earnings
Apr 01, 2027 (Est.)
EPS Estimate
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Specialty And Branded Pharmaceutical Platform

A presence across drug development, manufacturing, commercialization, and distribution gives the company multiple ways to capture value from its products. Its specialty and branded focus can support differentiated market positioning and recurring demand if product adoption is sustained.

Recent Revenue Rebound

The return to revenue growth after the earlier decline indicates that the company has regained some commercial momentum. If maintained, broader sales can improve fixed-cost absorption, support investment in products, and provide a foundation for future operating recovery.

Improving Gross Margin

The substantial gross-margin improvement suggests that the product mix or commercial economics became more favorable. Continued margin improvement could strengthen the earnings model, increase the contribution from incremental sales, and help narrow the gap between revenue growth and profitability.

Bears Say

Persistent Severe Unprofitability

Recurring losses at this magnitude show that revenue growth has not yet translated into a sustainable operating model. The wide gap between sales and both operating and net earnings limits internal funding capacity and makes a durable turnaround dependent on substantial cost improvement.

Stressed Capital Structure

Negative equity and high debt materially reduce financial flexibility and leave the company more exposed to refinancing and solvency pressure. This capital structure can constrain investment in products and commercialization while increasing the consequences of continued operating losses.

Recurring Cash Consumption

The renewed cash burn indicates that reported commercial recovery has not yet produced dependable cash generation. Persistent negative operating and free cash flow can increase reliance on external financing, limit strategic flexibility, and amplify execution risk while losses continue.

China NT Pharma Group Co., Ltd. News

1011 FAQ

What was China NT Pharma Group Co., Ltd.’s price range in the past 12 months?
China NT Pharma Group Co., Ltd. lowest stock price was HK$0.16 and its highest was HK$1.00 in the past 12 months.
What is China NT Pharma Group Co., Ltd.’s market cap?
China NT Pharma Group Co., Ltd.’s market cap is HK$346.74M.
When is China NT Pharma Group Co., Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were China NT Pharma Group Co., Ltd.’s earnings last quarter?
China NT Pharma Group Co., Ltd. released its earnings results on Aug 20, 2026. The company reported -HK$0.026 earnings per share for the quarter.
Is China NT Pharma Group Co., Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does China NT Pharma Group Co., Ltd. pay dividends?
China NT Pharma Group Co., Ltd. pays an annual dividend of HK$0.035 which represents an annual dividend yield of ―. See more information on China NT Pharma Group Co., Ltd. dividends here
What is China NT Pharma Group Co., Ltd.’s EPS estimate?
China NT Pharma Group Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China NT Pharma Group Co., Ltd. have?
China NT Pharma Group Co., Ltd. has 1,796,563,600 shares outstanding.
What happened to China NT Pharma Group Co., Ltd.’s price movement after its last earnings report?
China NT Pharma Group Co., Ltd. reported an EPS of -HK$0.026 in its last earnings report. Following the earnings report the stock price went down -4.688%.
Which hedge fund is a major shareholder of China NT Pharma Group Co., Ltd.?
Currently, no hedge funds are holding shares in HK:1011
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology